# Tenaya Therapeutics (TNYA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/TNYA
## Company Profile
- Ticker: TNYA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.7513 USD
- Market cap: 171429112.04000002 USD
- Last updated: 2026-08-11
## Business Overview
### Genetically Informed Cardiac Therapies
Tenaya Therapeutics develops gene therapies and small molecules that address underlying drivers of inherited and prevalent heart disease.
### TN-201
TN-201 is an AAV gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 mutations. The Phase 1b/2 MyPEAK-1 study is evaluating two dose cohorts in adults.
### TN-401
TN-401 is an AAV gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. RIDGE-1 is assessing safety, cardiac biomarkers and early measures of disease activity.
### TN-301
TN-301 is a selective HDAC6 inhibitor with potential applications in heart failure with preserved ejection fraction, Duchenne muscular dystrophy and other cardiac or muscular disorders.
### Discovery Collaborations
Tenaya combines internal target discovery with external collaborations, including work with Alnylam to identify and validate genetic targets for cardiovascular disease.
## Why The Stock Is Moving

As of Aug 11, 2026, TNYA closed up 1.89% at $0.7513. No new same-company headline was identified in the current news window.

## Future Catalysts

- One-year Cohort 1 and initial Cohort 2 RIDGE-1 data for TN-401 at ASGCT 2026.
- Updated Cohort 1 and Cohort 2 MyPEAK-1 data for TN-201 in the second quarter of 2026.

## Drug Assets

- TN-201

## Recent News
- 2026-08-05 20:05 EST — [Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2026-financial-results-and-provides-b-fdaeeca5) — Source: Tenaya Therapeutics
- 2026-08-04 20:05 EST — [Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-to-participate-in-the-canaccord-genuity-46th-annual-growth-c-f242d4ed) — Source: Tenaya Therapeutics
- 2026-07-15 01:00 EST — [Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-6852bd7a) — Source: Tenaya Therapeutics
- 2026-06-29 12:30 EST — [Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-appoints-eric-hyllengren-as-chief-financial-officer-bc693f44) — Source: Tenaya Therapeutics
- 2026-06-03 11:00 EST — [Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms](https://biopharmsignal.com/news/TNYA/tenaya-therapeutics-announces-interim-data-from-mypeaktm-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-reductions-in-symptoms) — Source: Tenaya Therapeutics